Achillion Pharmaceuticals Downgraded to Market Perform at JMP Securities (ACHN)
Achillion Pharmaceuticals (NASDAQ:ACHN) was downgraded by research analysts at JMP Securities from an “outperform” rating to a “market perform” rating in a report released on Monday, TheFlyOnTheWall.com reports.
Shares of Achillion Pharmaceuticals (NASDAQ:ACHN) traded down 51.66% during mid-day trading on Monday, hitting $3.50. The stock had a trading volume of 12,122,398 shares. Achillion Pharmaceuticals has a 52-week low of $6.12 and a 52-week high of $11.36. The stock has a 50-day moving average of $6.9 and a 200-day moving average of $7.42. The company’s market cap is $338.2 million.
A number of other analysts have also recently weighed in on ACHN. Analysts at Bank of America Corp. downgraded shares of Achillion Pharmaceuticals (NASDAQ:ACHN) from a “neutral” rating to an “underperform” rating in a research note to investors on Monday. They now have a $2.00 price target on the stock, down previously from $10.00. Separately, analysts at Robert W. Baird cut their price target on shares of Achillion Pharmaceuticals (NASDAQ:ACHN) from $16.00 to $12.00 in a research note to investors on Tuesday, July 2nd. They now have an “outperform” rating on the stock. Finally, analysts at Leerink Swann reiterated a “hold” rating on shares of Achillion Pharmaceuticals (NASDAQ:ACHN) in a research note to investors on Tuesday, July 2nd. One research analyst has rated the stock with a sell rating, eight have assigned a hold rating and two have issued a buy rating to the company. The stock presently has a consensus rating of “Hold” and a consensus price target of $7.08.
Achillion Pharmaceuticals, Inc is a biopharmaceutical company focused on the discovery, development and commercialization of treatments for infectious diseases.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.